Vasopressin Tannate

CHEMBL1201528 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

2785.4 g/mol

LogP

—

Phase

4

Vasopressin tannate is a prolonged-acting repository form of vasopressin combined with tannic acid, designed for intramuscular injection to provide slow release of vasopressin for the treatment of central diabetes insipidus. The tannate salt creates a depot formulation that extends the duration of antidiuretic activity compared to aqueous vasopressin, allowing less frequent dosing. It has been largely replaced by the synthetic vasopressin analog desmopressin (DDAVP).

Masse moléculaire

2785,4000 g/mol

TPSA

1290,00 Å²

Pharmacokinetics (PK)

Pharmacodynamics (PD)

SMILES

C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N.C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O

InChI

InChI=1S/C76H52O46.C46H65N15O12S2/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26;47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-20,52,63-65,76-101H,21H2;1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t52-,63-,64+,65-,76+;27-,28-,29-,30-,31-,32-,33-,34-/m10/s1

Molecular Formula

C122H117N15O58S2

HBD / HBA

39 / 62

Liaisons Rotatives

50

Atomes Lourds

197

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Vasopressin tannate is a prolonged-acting repository form of vasopressin combined with tannic acid, designed for intramuscular injection to provide slow release of vasopressin for the treatment of central diabetes insipidus. The tannate salt creates a depot formulation that extends the duration of antidiuretic activity compared to aqueous vasopressin, allowing less frequent dosing. It has been largely replaced by the synthetic vasopressin analog desmopressin (DDAVP).

Yes, Vasopressin Tannate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201528. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 165411857. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Vasopressin Tannate sur PillFYI

Données Clés

Formule: C122H117N15O58S2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.